| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
Quinic acid targets multiple enzymes and pathways. It acts as an inhibitor of monoamine oxidase (MAO), an enzyme responsible for the degradation of monoamine neurotransmitters. It also inhibits α-glucosidase, an enzyme involved in carbohydrate digestion. Quinic acid inhibits NF-κB activity in cells grown in tissue culture. As a cellular metal ion chelator, it can bind metal ions and modulate metal-dependent biological processes. It also exhibits antioxidant activity by scavenging reactive oxygen species such as hydrogen peroxide.
|
|---|---|
| ln Vitro |
In vitro, quinic acid demonstrates antioxidant activity by scavenging hydrogen peroxide with an IC₅₀ of 87.11 μg/mL. It inhibits MAO and α-glucosidase with IC₅₀ values of 93.75 μg/mL. Pre-incubation of MOVAS cells (mouse vascular smooth muscle cell line) for 2 hours with quinic acid (0.1, 1, and 10 μg/mL) dose-dependently inhibits TNF-α-induced mRNA and protein expression of VCAM-1 and monocyte adhesion. It inhibits NF-κB activity in cells grown in tissue culture. It also exhibits neuroprotective activity.
|
| ln Vivo |
In vivo, quinic acid is orally active. It exhibits antioxidant and anti-inflammatory effects in animal models. Its inhibition of α-glucosidase suggests potential benefits for glucose metabolism and diabetes management. As a metal ion chelator, it may modulate metal ion homeostasis in vivo. The compound is an endogenous metabolite naturally present in the human body and is also obtained from dietary sources such as fruits and vegetables. Its role as a shikimate pathway intermediate makes it a key compound in plant metabolism and a precursor to numerous plant secondary metabolites.
|
| Enzyme Assay |
In vitro enzyme assays for quinic acid typically measure MAO inhibition using a fluorometric or colorimetric method. MAO enzyme (from rat brain or recombinant) is incubated with varying concentrations of quinic acid in assay buffer (50 mM sodium phosphate, pH 7.4) at 37°C for 30 minutes. The substrate (kynuramine or tyramine) is added, and the reaction product (4-hydroxyquinoline for MAO-A) is measured fluorometrically at excitation/emission wavelengths of 310/400 nm. For α-glucosidase inhibition, the enzyme is incubated with quinic acid and p-nitrophenyl-α-D-glucopyranoside as substrate at 37°C for 20 minutes, and absorbance is measured at 405 nm. For antioxidant activity, the hydrogen peroxide scavenging assay measures the reduction of H₂O₂ by the compound.
|
| Cell Assay |
In vitro cell-based assays for quinic acid typically use MOVAS mouse vascular smooth muscle cells. Cells are cultured in DMEM with 10% FBS at 37°C in 5% CO₂. Cells are pre-incubated with quinic acid (0.1, 1, and 10 μg/mL) for 2 hours, then stimulated with TNF-α (10 ng/mL) for 4-6 hours. VCAM-1 mRNA and protein expression is measured by RT-PCR and Western blot, respectively. Monocyte adhesion assays are performed by adding fluorescently labeled monocytes to the treated endothelial cell monolayer and measuring fluorescence after washing. NF-κB activity is assessed by reporter gene assays or by measuring p65 nuclear translocation via immunofluorescence. Cytotoxicity is evaluated by MTT assays.
|
| Animal Protocol |
In vivo animal studies with quinic acid typically use rodent models. For inflammation studies, mice or rats are administered quinic acid orally (e.g., 50-200 mg/kg) or intraperitoneally, followed by induction of inflammation (e.g., carrageenan-induced paw edema or LPS-induced systemic inflammation). Inflammatory markers (TNF-α, IL-6, IL-1β) are measured in serum or tissue homogenates by ELISA. For diabetes studies, diabetic mice are treated with quinic acid and blood glucose levels are monitored. For neuroprotective studies, animal models of neurodegeneration are used with behavioral assessments and histopathological examination of brain tissue.
|
| ADME/Pharmacokinetics |
Quinic acid is orally active. As an endogenous metabolite, it is naturally present in the human body and is absorbed from dietary sources. Its pharmacokinetics as a therapeutic agent have not been extensively characterized. The compound has a molecular weight of 192.17 g/mol and is highly water-soluble due to its multiple hydroxyl groups. It is rapidly absorbed and distributed to tissues. Metabolism likely involves conjugation and oxidation, with renal excretion as the primary elimination pathway. Its role as a shikimate pathway intermediate suggests it is involved in various metabolic pathways.
|
| Toxicity/Toxicokinetics |
Quinic acid has low inherent toxicity as it is an endogenous metabolite and a common dietary component. It is generally recognized as safe (GRAS) for consumption. The compound does not show significant cytotoxicity at concentrations relevant to its biological activities. It is not classified as a carcinogen, mutagen, or reproductive toxicant. In animal studies, high doses are well-tolerated with no significant adverse effects. The compound's safety profile is favorable for both research and potential therapeutic applications. As a research chemical, standard laboratory safety practices should be followed.
|
| Additional Infomation |
(-)-quinic acid is the (-)-enantiomer of quinic acid, the conjugate acid of (-)-quinic acid salt, and also the enantiomer of (+)-quinic acid. Quinic acid has been reported to be found in tea (Camellia sinensis), dodder (Cuscuta reflexa), and other organisms with relevant data. Quinic acid is also found in cinchona bark and other plants. (From Stedman, 26th edition)
Quinic acid is an endogenous cyclitol carboxylic acid and a central intermediate of the shikimate pathway. It is the core scaffold of chlorogenic acids. Synonyms include Kinic acid and Chinic acid. It is a cellular metal ion chelator capable of promoting reactions with metal ions under pH-specific conditions. It exhibits antioxidant activity and is an inhibitor of MAO and α-glucosidase. It has inherent biological activity as a neuroprotectant. Quinic acid is used as a versatile chiral scaffold in organic synthesis. This product is intended for research and analytical applications. |
| Molecular Formula |
C7H12O6
|
|---|---|
| Molecular Weight |
192.1666
|
| Exact Mass |
192.063
|
| CAS # |
77-95-2
|
| PubChem CID |
6508
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
438.4±45.0 °C at 760 mmHg
|
| Melting Point |
165-170 °C
|
| Flash Point |
233.1±25.2 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.687
|
| LogP |
-2.01
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
203
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1[C@H](C([C@@H](CC1(C(=O)O)O)O)O)O
|
| InChi Key |
AAWZDTNXLSGCEK-LNVDRNJUSA-N
|
| InChi Code |
InChI=1S/C7H12O6/c8-3-1-7(13,6(11)12)2-4(9)5(3)10/h3-5,8-10,13H,1-2H2,(H,11,12)/t3-,4-,5?,7?/m1/s1
|
| Chemical Name |
(3R,5R)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~650.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (520.37 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2037 mL | 26.0186 mL | 52.0373 mL | |
| 5 mM | 1.0407 mL | 5.2037 mL | 10.4075 mL | |
| 10 mM | 0.5204 mL | 2.6019 mL | 5.2037 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01912144 | COMPLETED | Other: Coffee | Bioavailability Cardiovascular Health Status | University of Leeds | 2012-09-01 | Not Applicable |
| NCT04095949 | COMPLETED | Dietary Supplement: Artichokes | Healthy Men and Women | King's College London | 2019-07-17 | Not Applicable |
| NCT00065715 | COMPLETED | Dietary Supplement: Echinacea Other: Blinded placebo |
Common Cold | University of Wisconsin, Madison | 2003-09 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
